<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03722407</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-19727</org_study_id>
    <nct_id>NCT03722407</nct_id>
  </id_info>
  <brief_title>Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion</brief_title>
  <official_title>A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study
      drug (ruxolitinib) can improve outcomes of patients with CMML.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response</measure>
    <time_frame>At week 16</time_frame>
    <description>Proportion of participants achieving clinical benefit defined as hematologic improvement, complete remission, partial remission, or stable disease by the International Working Group Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Acute Myeloid Leukemia (AML) transformation</measure>
    <time_frame>Every 6 months after conclusion of treatment until end of study (24 months)</time_frame>
    <description>Time to AML transformation according to World Health Organization (WHO) Critieria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Overall survival will be from first dose of study drug until failure or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Duration of response measured using time to AML transformation according to WHO Critieria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in symptom score</measure>
    <time_frame>Baseline, Week 17</time_frame>
    <description>Change in symptom score as defined by the Myeloproliferative Neoplasms Symptom Assessment Form-Total Symptom Score (MPN-SAF TSS). The MPN -SAF TSS scores symptoms of myeloproliferative neoplasm by rankings of 0 (symptom is absent) to 10 (Worst imaginable)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pathological Response</measure>
    <time_frame>Baseline, Week 17</time_frame>
    <description>&gt;/- 35% decrease in splenic volume as measured by CT scan</description>
  </other_outcome>
  <other_outcome>
    <measure>Mutational Status</measure>
    <time_frame>Baseline up to end of study (24 months)</time_frame>
    <description>Mutational Status in CMML patients measured by sanger sequencing of JAK2, c-CBL, N-RAS, K-RAS, RUNX-1, TET2, SRSF2, EZH2, ASXL1 and DNMT3a.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be given their first dose of oral Ruxolitinib, 20 mg at first scheduled visit. After that dose and on all other days patients will self-administer oral Ruxolitinib at a dose of 40 mg daily divided into two equal doses approximately 12 hours apart. Patients will be treated for a total of 16 weeks. After treatment, patients will be followed monthly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Ruxolitinib 5 mg tablets, 4 per dose</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <other_name>Jakafi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of Chronic Myelomonocytic Leukemia (CMML)using the World Health
             Organization (WHO) classification.

          -  18 years of age or older at the time of obtaining informed consent.

          -  Must be able to adhere to the study visit schedule and other protocol requirements.

          -  Participants must be able to provide adequate BM aspirate and biopsy specimens for
             histopathological analysis and standard cytogenetic analysis during the screening
             procedure.

          -  An Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 is
             required.

          -  Women of childbearing potential must agree to use two reliable forms of contraception
             simultaneously or to practice complete abstinence from heterosexual intercourse 1) for
             at least 28 days before starting study drug; 2) while participating in the study; and
             3) for at least 28 days after discontinuation from the study.

          -  Must understand and voluntarily sign an informed consent form.

          -  Must have a life expectancy of greater than 3 months at time of screening.

          -  Must have symptomatic splenomegaly and/or an Myeloproliferative Neoplasms Symptom
             Assessment Form Total Symptom Score &gt;17.

        Exclusion Criteria:

          -  Any of the following lab abnormalities: Platelet count of less than 35,000/uL,
             Absolute Neutrophil Count (ANC) less than 250/uL, Serum Creatinine â‰¥ 2.0, Serum total
             bilirubin &gt;1.5x ULN

          -  Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not
             commercially available) for the treatment of CMML within 28 days of the first day of
             study drug treatment.

          -  Prior history of metastatic malignancy in past 2 years

          -  Any serious medical condition or psychiatric illness that will prevent the subject
             from signing the informed consent form or will place the subject at unacceptable risk
             if he/she participates in the study.

          -  Concurrent use of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF).
             Granulocyte Colony Stimulating Factor (G-CSF) could be used for the short-term
             management of neutropenic infection. Stable doses of erythropoietin stimulating agents
             that were started &gt;8 weeks from first ruxolitinib dose or corticosteroids that were
             being administered prior to screening are allowed.

          -  Uncontrolled current illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant women are excluded from this study because ruxolitinib has not been studied
             in pregnant participants. Because there is an unknown but potential risk for adverse
             events in nursing infants secondary to treatment of the mother with ruxolitinib,
             breastfeeding should be discontinued if the mother is treated with ruxolitinib.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Padron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rahil Ismail</last_name>
    <phone>813-745-3825</phone>
    <email>Rahil.Ismail@moffitt.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahil Ismail</last_name>
      <phone>813-745-3825</phone>
      <email>Rahil.Ismail@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Eric Padron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rami Komrokji, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey E Lancet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kendra Sweet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bijal Shah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Sallman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chetasi Talati, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Kuykendall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Balasis, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Geisler</last_name>
      <phone>617-632-4912</phone>
      <email>margaretb_geisler@dfci.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anna Colbert</last_name>
      <phone>617-632-6363</phone>
      <email>Annaj_Colbert@dfci.hardvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Steensma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikkael A Sekeres, MD, MS</last_name>
      <phone>216-445-9353</phone>
      <email>sekerem@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Anjali Advani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aaron Gerds, MD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sudipto Mukherjee, MD, PhD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aziz Nazha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hetty Carraway, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronald Sobecks, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Betty Hamilton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yogen Sauntharaarajah, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barb Tripp, CNS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bhumika Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaroslaw Maciejewski, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://moffitt.org/clinical-trials-research/clinical-trials/</url>
    <description>Moffitt Cancer Center Clinical Trials Website</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

